Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19

Hage, René; Steinack, Carolin; Gautschi, Fiorenza; Pfister, Susan; İnci, İlhan; Schuurmans, Macé M.

doi:10.3390/transplantology2020022

Cited by 5 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azzi et al raised the hypothesis that SARS-CoV-2 infection could differ depending on the type of organ transplanted [7,20,21]. Although previous manuscripts identified recipients of different organs in their cohorts, patients were not classified according to the organ grafted, and no comparison between the different SOTs was carried out [10,22].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Severity and Mortality in Solid Organ Transplantation: Differences between Liver, Heart, and Kidney Recipients

Alberca

Netto

et al. 2021

Transplantology

View full text Add to dashboard Cite

The infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) can generate a wide spectrum of clinical manifestations ranging from asymptomatic to severe respiratory and systemic disease with coagulation disorder named coronavirus disease 2019 (COVID-19). Patients with comorbidities have been identified as risk groups for severe COVID-19, also having a higher death risk. Previous reports have conflicting results regarding if solid organ transplant recipients present an increased risk for COVID-19. Nevertheless, previous investigations failed to distinguish between different organs received or made a longitudinal investigation on those patients. We recruited 39 solid organ transplant recipients: 25 kidney transplant recipients, 7 heart transplant recipients, and 7 liver transplant recipients and 25 age-matched non-transplant COVID-19 patients without comorbidities (control group) and compared daily laboratory data in addition to performing survival analysis. Heart and kidney transplant recipients presented an increase in several COVID-19 severity-associated biomarkers, such as neutrophil-to-lymphocyte ratio and thrombocytopenia, in comparison to the control group and liver transplant recipients. Heart and kidney transplant recipients also presented an increase in the need for intensive care and invasive mechanical ventilation during the disease’s course. Importantly, heart and kidney transplant recipients presented a higher mortality rate in comparison to liver transplant recipients and non-transplant recipients. In our cohort, heart and kidney transplant recipients presented a difference in clinical characteristics and survival rate in comparison to liver transplant recipients. Further investigation involving immune response to SARS-CoV-2 in solid organ recipients should consider and separate patients according to the organ grafted.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Severity and Mortality in Solid Organ Transplantation: Differences between Liver, Heart, and Kidney Recipients

Alberca

Netto

et al. 2021

Transplantology

View full text Add to dashboard Cite

show abstract

“…Patients were classified as "moderate" COVID-19 when the clinical symptoms including dyspnea with or without hypoxia and where chest imaging was abnormal (infiltrates and/or ground-glass opacities). The baseline characteristics of these patients were published previously [21]. Full recovery was defined as two negative SARS-CoV-2 RT-PCR tests at least 24 h apart along with the resolution of symptoms.…”

Section: Methodsmentioning

confidence: 99%

COVID-Related Chronic Allograft Dysfunction in Lung Transplant Recipients: Long-Term Follow-up Results from Infections Occurring in the Pre-vaccination Era

Hage

Schuurmans

2022

Transplantology

Self Cite

View full text Add to dashboard Cite

Introduction: We report on characteristics and lung function outcomes among lung transplant recipients (LTRs) after COVID-19 with infections occurring in the first year of the coronavirus pandemic prior to introduction of the vaccines. Methods: This was a retrospective study of 18 LTRs who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. The mean age was 49.9 (22–68) years; 12 patients (67%) were male. Two patients died due to severe COVID-19. Results: During the study period, there were 18 lung transplant recipients with a community-acquired SARS-CoV-2 infection. In this cohort, seven had mild, nine had moderate, and two had severe COVID-19. All patients with mild and moderate COVID-19 survived, but the two patients with severe COVID-19 died in the intensive care unit while intubated and on mechanical ventilation. Most patients with moderate COVID-19 showed a permanent lung function decrease that did not improve after 12 months. Conclusion: A majority of LTRs in the current cohort did not experience an alteration in the trajectory of FEV1 evolution after developing SARS-CoV-2 infection. However, in the patients with moderate COVID-19, most patients had a decline in the FEV1 that was present after 1 month after recovery and did not improve or even deteriorated further after 12 months. In LTRs, COVID-19 can have long-lasting effects on pulmonary function. Treatment strategies that influence this trajectory are needed.

show abstract

COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients

Ennis,

Levvey,

Shingles

et al. 2024

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19

Cited by 5 publications

References 62 publications

COVID-19 Severity and Mortality in Solid Organ Transplantation: Differences between Liver, Heart, and Kidney Recipients

COVID-19 Severity and Mortality in Solid Organ Transplantation: Differences between Liver, Heart, and Kidney Recipients

COVID-Related Chronic Allograft Dysfunction in Lung Transplant Recipients: Long-Term Follow-up Results from Infections Occurring in the Pre-vaccination Era

COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients

Contact Info

Product

Resources

About